molgramostim

LANGHORNE, Pa., April 15, 2026 Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced that the...

Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...

LANGHORNE, Pa., November 2, 2025 — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases,...